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background:  Limited clinical reports are available on the response of hypertensive subjects to renal denervation (RDN) in an Asian 
population. The Global SYMPLICITY Registry (GSR) is a prospective, all-comer, worldwide registry that evaluates the safety and 
effectiveness of RDN, and includes the Korean registry (GSR Korea).
Methods:  The aim of the present study was to evaluate 6- and 12-month outcomes after RDN in GSR Korea subjects and to compare their 
outcomes with those of SYMPLICITY HTN-2, which enrolled a primarily Caucasian population with similar inclusion and exclusion criteria.
Results:  GSR Korea subjects (N=102) compared with SYMPLICITY HTN-2 subjects (N=89) had lower baseline office SBP (170 ± 15 
mm Hg vs. 184 ± 19 mm Hg, respectively, p<0.001), and also lower body mass index, higher estimated glomerular filtration rate, and 
differences in medications. Subjects in GSR Korea received more radiofrequency ablations during the procedure (15 ± 6 vs. 11 ± 2, 
p<0.001). Although the 6-month SBP reduction was less in GSR Korea than in HTN-2 there was no difference at 12 months (Figure). In 
GSR Korea there were no protocol-defined procedure-related adverse events and no chronic adverse events associated with the device.
conclusion:  RDN provided a similar and significant reduction in 12-month SBP of approximately 26 mm Hg in both Asian and Caucasian 
populations with a favorable safety profile.
 
